Arrowhead Research Corporation Status update

Please go ahead, Vince. Thank you, Tara, and thanks everybody for joining us today.

We're excited to present the data that we presented yesterday at the European Society of Cardiology in Munich, for what we think is groundbreaking data from the SHASTA III and IV studies of plozasiran. Before we start, just want to make sure everybody knows that we will be making forward-looking statements today, so refer to our SEC filings for risk factors. I also want to remind people that the SHTG indication has not been reviewed or approved by any regulatory authorities around the world, so it should be considered investigational. The results here are preliminary, so they should not be used for HCPs or patients or in product promotion in any way. This is an investor-focused communication today. We're very fortunate today to have two external speakers who are leaders in the field.

Dr. Gerald Watts from The University of Western Australia in Perth, who gave our hotline late-breaker presentation yesterday. Also Dr. Børge Nordestgaard from Copenhagen University Hospital, who was the discussant for our presentation yesterday. Here's the flow. Today I'll give a short introduction and a review of Arrowhead generally in the cardiometabolic pipeline. Dr. Jennifer Helliwell, who is head of clinical development at Arrowhead, will talk about severe hypertriglyceridemia or SHTG. Again, Dr. Watts will do an encore presentation of the SHASTA III and IV full results. Dr. Nordestgaard will give a discussion on the results and the clinical implications. Andy Davis, our head of cardiometabolic commercial, will talk about the current status of our commercialization efforts in SHTG. Then I'll give some key takeaways, and then we'll have a little bit of time at the end for you to ask questions to the panel.

It'll be a limited amount of time, so we should be able to take maybe 5 or 6 questions.